10-Q quarterly report · filed Nov 5, 2026

GRAIL, Inc. (GRAL) Q3 2026 10-Q Quarterly Report

Short answer

GRAIL, Inc. (GRAL) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $38M (up 3.7% year over year) with net income of −$104M.

Q3 2026 key financials · XBRL

Revenue
$38M
+3.7% YoY · −16.0% QoQ
Net income
−$104M
−16.4% YoY · +6.1% QoQ
Operating margin
-385.3%
EPS (diluted)
−$1.98
+19.2% YoY · +23.0% QoQ

Source: XBRL data from the GRAIL, Inc. (GRAL) Q3 2026 10-Q on SEC EDGAR. USD.

GRAIL, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $37.5M, up $1.3M YoY, driven by screening revenue $37.3M, up 14%
  • Adjusted gross margin 42% vs 55% YoY, with screening cost ratio up approximately 11 percentage points
  • Screening best performer: Galleri volume up 24%; development services revenue fell 92% to $0.1M
  • Cash and securities $788.7M at September 30; operating cash used $242.5M versus $235.2M YoY
  • Samsung financing generated $109.0M; FDA decision expected by early first quarter 2027, broader reimbursement remains unavailable

Risk Factors

  • New securities litigation risk: June 2026 Robbins class action and Augitto derivative action allege misleading NHS-Galleri Trial disclosures
  • New intellectual-property risk: September 2026 Clinical Genomics lawsuit alleges Galleri infringes two U.S. patents
  • FDA approval risk updated: September 2026 advisory panel supported Galleri, but FDA may delay, restrict, or deny PMA approval
  • Pricing risk updated: September 2026 promotional reductions may increase demand while lowering average selling prices and margins
  • Regulatory risk reduced: SEC investigation into Illumina’s GRAIL-related disclosures closed May 9, 2025

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other GRAIL, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.